Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in human African trypanosomiasis.

Reto Brun1, Oliver Balmer

  • 1Swiss Tropical Institute, Parasite Chemotherapy, Basel, Switzerland. reto.brun@unibas.ch

Current Opinion in Infectious Diseases
|August 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic characterization of schistosome species from cattle in Côte d'Ivoire.

Parasites & vectors·2024
Same author

Key Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases.

Chimia·2023
Same author

Prevalence and risk factors of schistosomiasis and hookworm infection in seasonal transmission settings in northern Côte d'Ivoire: A cross-sectional study.

PLoS neglected tropical diseases·2023
Same author

Investigation of the effect of structure modification of furamidine on the DNA minor groove binding and antiprotozoal activity.

European journal of medicinal chemistry·2023
Same author

Michellamines A<sub>6</sub> and A<sub>7</sub>, and further mono- and dimeric naphthylisoquinoline alkaloids from a Congolese <i>Ancistrocladus</i> liana and their antiausterity activities against pancreatic cancer cells.

RSC advances·2022
Same author

Antiprotozoal dimeric naphthylisoquinolines, mbandakamines B<sub>3</sub> and B<sub>4</sub>, and related 5,8'-coupled monomeric alkaloids, ikelacongolines A-D, from a Congolese <i>Ancistrocladus</i> liana.

RSC advances·2022

Recent advancements in human African trypanosomiasis research include the Trypanosoma brucei genome completion, aiding drug discovery. New diagnostic methods and promising drug candidates are emerging, alongside insights into animal reservoirs for this neglected tropical disease.

Area of Science:

  • Molecular biology
  • Parasitology
  • Genomics

Background:

  • Human African trypanosomiasis (HAT) remains a significant public health challenge.
  • Progress in understanding and combating HAT is crucial for affected populations.

Purpose of the Study:

  • Review recent literature on HAT.
  • Focus on genome sequencing, diagnosis, drug discovery, and trypanosome typing.

Main Methods:

  • Analysis of the completed Trypanosoma brucei genome.
  • Evaluation of novel diagnostic methods, including sleep pattern analysis.
  • Assessment of new drug candidates, such as dicationic molecules.
  • Review of molecular typing techniques (MGE-PCR, microsatellites).

Main Results:

Related Experiment Videos

  • The Trypanosoma brucei genome facilitates new drug target and genetic marker discovery.
  • Sleep pattern analysis shows promise for disease staging and clinical trials.
  • Dicationic molecules, including an oral diamidine, are promising drug candidates.
  • New typing methods (MGE-PCR, microsatellites) enable analysis without parasite cultivation.
  • Identification of wild animal reservoirs for T. b. gambiense highlights transmission dynamics.

Conclusions:

  • The Trypanosoma brucei model system yields new diagnostic technologies and drugs.
  • Public-private partnerships are revitalizing drug discovery and development for HAT.
  • Translating scientific progress into tangible benefits for affected communities remains a key challenge.